Related Experiment Video
Updated: Feb 10, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Pembrolizumab-induced acute thrombosis: A case report
Kei Kunimasa1, Kazumi Nishino, Madoka Kimura
1Department of Thoracic Oncology, Osaka International Cancer Institute, Otemae Chuoku, Osaka City, Japan.
Acute thrombosis is a rare immune-related adverse event (irAE) in lung cancer patients treated with PD-1 inhibitors like pembrolizumab. Early heparin treatment managed symptoms, allowing continued therapy and tumor shrinkage.
Area of Science:
- Oncology
- Immunology
- Vascular Medicine
Background:
- Immune-related adverse events (irAEs) are known complications of PD-1 pathway inhibitors.
- Acute thrombosis has not been previously reported as an irAE in lung cancer patients receiving these therapies.
Observation:
- Two non-small cell lung cancer (NSCLC) patients developed acute thrombosis during pembrolizumab treatment.
- Diagnosis was confirmed via D-dimer testing, venous ultrasonography, and enhanced CT scans.
Findings:
- Immediate treatment with continuous heparin infusion resolved thrombosis symptoms.
- Patients successfully continued pembrolizumab therapy combined with direct oral anticoagulants (DOACs), achieving tumor shrinkage.
Implications:
- Pembrolizumab-induced T-cell activation may trigger systemic inflammation, leading to thrombosis.
- Recognizing and managing this rare irAE is crucial to prevent treatment cessation and potential mortality.
Related Concept Videos
Venous Thrombosis I: Introduction
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management

